Strategies for Pharmacovigilance in Medical Institutions Based on Closed-Loop Model of Risk Management

doi:10.19803/j.1672-8629.20250645

Abstract

Abstract: Objective To explore strategies for pharmacovigilance in medical institutions in order to provide a reference for related pharmacovigilance systems. Methods By analyzing the current practices and priorities related to pharmacovigilance in medical institutions, the challenges to construction of systems, risk identification, and processes of management were investigated while schemes for optimization were devised based on concepts of risk control. Results Strategies for optimization were proposed, and a closed-loop management model was established using a “monitoring-assessment-intervention-feedback” framework. Conclusion This study is expected to improve the ability of medical institutions to monitor, identify, assess drug risks, and provide feedback.

Key words: Risk Management, Medical Institutions, Pharmacovigilance, Adverse Drug Reaction, Drug Risk Management

CLC Number:

R954
R994.11

XU Zhuoxin, ZHANG Bing, ZHANG Xiaomeng, MENG Min, SA Rina. Strategies for Pharmacovigilance in Medical Institutions Based on Closed-Loop Model of Risk Management[J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 438-442.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250645

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I4/438

References

[1] WANG D, DONG Z, TIAN CH.Course of Development of Pharmoco-vigilance Systems in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 735-740.
[2] National Medical Products Administration. Announcement on Issuing Guideline on Good Pharmacovigilance Practices[EB/OL]. (2021-05-13)[2026-03-02]. https://www.nmpa.gov.cn/xxgk/ggtg/20210513151827179.html.
[3] LIN GB, LI Y, XIE HZ, et al.Analysis of 69 ADR Reports of Novelty Caused by Chinese Patent Medicines[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2023, 16(22): 141-143.
[4] SUN WJ, HU Y, XU Y, et al.Research Progress of Antitumor Pharmacovi-gilance[J]. Chinese Journal of Lung Cancer(中国肺癌杂志), 2022, 25(7): 541-545.
[5] WANG GP, SHEN K, XU JL.Development and Status of Pharma-covigilance Data Sharing and Data Exchange in China[J]. Chinese Journal of Medicinal Guide(中国医药导刊), 2024, 26(8): 790-796.
[6] SONG H, PEI X, LIU Z, et al.Pharmacovigilance in China: Evolution and Future Challenges[J]. Br J Clin Pharmacol, 2023, 89(2): 510-522.
[7] JOYNER LM, ALICEA LA, GOLDMAN JL, et al.Methods for Detecting Pediatric Adverse Drug Reactions From the Electronic Medical Record[J]. J Clin Pharmacol, 2021, 61(11): 1479-1484.
[8] SALAS M, PETRACEK J, YALAMANCHILI P, et al.The Use of Artificial Intelligence in Pharmacovigilance: a Systematic Review of the Literature[J]. Pharmaceut Med, 2022, 36(5): 295-306.
[9] BANERJEE R, ERRIDGE S, SALAZAR O, et al.Real World Evidence in Medical Cannabis Research[J]. Ther InnovRegul Sci, 2022, 56(1): 8-14.
[10] LIU PC, ZHU Z, LIU F.Expert Consensus on Construction of Pharmacovigilance System in Health Facilities[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2022, 19(3): 135-144.
[11] SUN XL, QIAN DF, ZHANG YT, et al.Discussion on the Construction of Risk Management System of Drug Use in China[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2021, 38(6): 499-503.
[12] JIANG HC, NI WJ, WU ZB.High-Alert Drug Management and Risk Control in Our Hospital[J]. China Pharmacy(中国药房), 2021, 32(9): 1108-1113.
[13] WANG M.Current Situation of Adverse Drug Reaction Monitoring in Hospitals and Related Countermeasures[J]. Pharmaceutical Care and Research(药学服务与研究), 2016, 16(5): 359-362.
[14] WANG N, ZHANG KH.Practice and Reflection of Pharmacovigilance System Construction[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2023, 32(11): 1217-1224.
[15] HOU YF, SONG HB, LIU HL, et al.Practice and Discussion on Active Surveillance by China Hospital Pharmacovigilance System[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 212-214.
[16] ZHANG YJ, CHEN H, YANG Y.Preliminary Thinking on the Estab-lishment of China’s Future Pharmacovigilance System[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(22): 2017-2023.
[17] LIU Y, ZHAO W, LIU YY, et al.Identifying and Responding to Interface Risk of Hospital Medicine Management Based upon DealthcareFailure Modes and Effects Analysis[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2024, 44(11): 1338-1344.
[18] GAO YJ, ZHAO X, BAI TK, et al.Discovery and Identification Strategy for Drug Safety Risks Based on Big Data Monitoring of Adverse Reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(1): 1-5, 14.
[19] ARNAUD M, BÉGAUD B, THURIN N, et al. Methods for Safety Signal Detection in Healthcare Databases: a Literature Review[J]. Expert Opin Drug Saf, 2017, 16(6): 721-732.
[20] ZHAO Y, YU Y, WANG H, et al.Machine Learning in Causal Inference: Application in Pharmacovigilance[J]. Drug Saf, 2022, 45(5): 459-476.
[21] WANG W, QI YF, BAO H, et al.Establishment of the Clinical Evaluation System of Precision Pharmacy Based on Medical Big Data[J]. Chinese Pharmaceutical Affairs(中国药事), 2017, 31(12): 1478-1482.
[22] YU JS, LI Q, CUI Y.Research Progress of Personalized Treatment for Cancer Patients with Chemotherapy Drugs Using Genomics and Quantitative Pharmacology[J]. Chinese Journal of Marine Drugs(中国海洋药物), 2024, 43(6): 73-82.
[23] LIU FM, ZHANG L, LI YY, et al.Guidelines for Construction of Traditional Chinese Medicine Pharmacovigilance System in Medical Institutions[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2024, 49(16): 4266-4272.
[24] WANG L, RASTEGAR-MOJARAD M, JI Z, et al.Detecting Pharmacovigilance Signals Combining Electronic Medical Records with Spontaneous Reports:a Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis[J]. Front Pharmacol, 2018, 9: 875.
[25] KUMAR RKS, VELUSAMY S.Harnessing Artificial Intelligence for Enhanced Pharmacovigilance: a Comprehensive Review[J]. Ind J Pharm Pract, 2025, 18(2): 171-179.
[26] ZHANG L, MEI ZC, PAN CB, et al.Evaluation on the Effect of Infection Risk Prevention and Control Management in Mobile Cabin Hospitals Based on the Risk Matrix Method[J]. Chongqing Medical Journal(重庆医学), 2023, 52(7): 1109-1112.
[27] SHI DN, WAN J, CHEN WD, et al.Research on Pharmacovigilance of Vancomycin in Children Based on Real World Data[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2025, 42(22): 3913-3922.
[28] GARCíA-ABEIJON P, COSTA C, TARACIDO M, et al. Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: a Systematic Review Update[J]. Drug Saf, 2023, 46(7): 625-636.